Hebei Huachen Pharmaceutical Co. Ltd.

Primary objective: To observe the pharmacokinetic characteristics of the test preparation Topiramate Tablets (Specification: 60 mg; Manufacturer: Hebei Huachen Pharmaceutical Group Co., Ltd.) and the reference preparation Topiramate Tablets (Trade name: Topiloric®; Specification: 60 mg; Licensee: Fuji Pharmaceutical Co., Ltd.) after a single oral administration in the fasting/postprandial state in healthy Chinese subjects, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. Secondary objective: To observe the safety of the test preparation Topiramate Tablets and the reference preparation Topiramate Tablets (Topiloric®) in healthy Chinese subjects.

Main study objectives: To investigate the relative bioavailability of a single oral dose of 75 mg (fasting/postprandial) of the test formulation oseltamivir phosphate dry suspension [Specification: 0.36 g (calculated as C16H28N2O4), produced by Hebei Huachen Pharmaceutical Group Co., Ltd.] and the reference formulation oseltamivir phosphate dry suspension [trade name: Tamiflu®, specification: 6 mg/mL (calculated as C16H28N2O4) (calculated as C16H28N2O4), licensed by HOFFMANN LA ROCHE INC, produced by F.Hoffmann-La Roche Ltd] in healthy Chinese subjects, analyze the pharmacokinetic parameters of the two formulations, and evaluate the bioequivalence of the two formulations. Secondary study objectives: To evaluate the safety of a single oral dose of the test formulation and the reference formulation on an empty stomach/postprandial basis in healthy Chinese adult subjects.

Primary objective: This study aims to investigate the pharmacokinetic characteristics of a single fasting application of levocaine cream (30 g: lidocaine 0.75 g, prilocaine 0.75 g) developed and produced by Hebei Huachen Pharmaceutical Group Co., Ltd. in healthy study participants; using levocaine cream (Emla®, 1 g: lidocaine 25 mg, prilocaine 25 mg) licensed by Aspen Pharma Trading Limited and produced by Recipharm Karlskoga AB as the reference preparation, to compare the pharmacokinetic parameters Cmax, AUC0-t and AUC0-∞ of the two preparations, and to evaluate the bioequivalence of the two preparations in humans. Secondary objective: To observe the safety of the test preparation and the reference preparation after a single application in healthy study participants. Secondary objective: To observe the safety of the test preparation and the reference preparation after a single application in healthy study participants.